Scientists have discovered a key protein that could be targeted with a drug to treat the most common and aggressive form of pancreatic cancer. 

The findings, published in Nature, show that blocking the protein SPP1 could stop the spread of the cancer and increase survival time. 

 More than 10,000 people are diagnosed with pancreatic cancer in the UK each year, and there are more than 9,000 deaths from the disease each year. Survival rates have not shown improvement in the past 50 years and the disease has the lowest survival rates of common cancers. Only five in 100 people will survive for ten years or more. 

 Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive type of pancreatic cancer, and the most common, accounting for 90% of pancreatic cancers. 

Researchers from The Institute of Cancer Research (ICR) in London found that levels of the SPP1 protein were raised in the advanced stages of pancreatic cancer, compared with stage 1 and 2. Looking at data from 644 patients’ tumours, patients with higher levels of SPP1 had worse outcomes. 

 The team, funded by the ICR and Breast Cancer Now, grew pancreatic cancer organoids, lab-grown mini tumours designed to model how cancer cells behave in our bodies. When researchers switched off the gene to make the SPP1 protein, fewer and smaller tumours developed than when the protein was present. There were also fewer cells with properties helping them invade new tissues and migrate around the body, considered to be dangerous cells. 

“A few years ago, we made a fundamental discovery in understanding what drives pancreatic cancer to be able to spread – making it less treatable, and ultimately more dangerous,” said Axel Behrens, Professor of Stem Cell Biology at The Institute of Cancer Research, London, and Scientific Director of the Cancer Research UK Convergence Science Centre.  

“Our research has identified a protein that, when blocked, can prevent cancer from spreading around the body and can hopefully keep patients living well for longer. The next step for this research will be to develop a drug that can precisely target the protein.” 

Results in mice confirm findings 

Researchers also tested the method in mice with PDAC, and switching off the gene significantly extended their survival. None of the mice with the gene survived past 50 days, whereas 20% of the mice without the gene survived to 400 days. The mice with the SPP1 gene switched off had tumours which did not spread at all. 

Giving the mice an antibody to target the SPP1 protein also extended survival and prevented cancer spread. Without the antibody, half of the mice survived 30 days but with the antibody, half survived beyond 100 days. 

“Pancreatic cancer remains a devastating diagnosis for patients, as its most common form spreads aggressively, and is difficult to treat,” added Kristian Helin, Chief Executive of Cancer Research, London. 

“This exciting research offers hope, identifying a clear target to halt the spread of the disease. It’s an important step toward more effective treatments, and I look forward to future drug discovery efforts building on these findings to provide new options to patients in urgent need.” 

 

Bruno Quinney, Content Team, DDW